Ribavirin and peg-interferon with or without adjuvant therapy with erythropoietin in patients with hepatitis C: a randomised controlled trial
Abstract number: P1898
Petrov M., Piskunova N., Anosov A.
Background: It has been established that dose reduction of Ribavirin and interferon leads to reduction in end of treatment and sustained virological response. Erythropoietin can be used to minimise the dose reduction. However, its effect has not been investigated in the randomised controlled trial yet. Thereby, our objective was to assess the effect of erythropoietin therapy on the Ribavarin and Peg interferon dose reduction in patients with hepatitis C.
Methods: Ninety-four patients with hepatitis C who received Ribavarin plus Peg interferon therapy were randomised to erythropoietin (n = 46) or no erythropoietin (n = 48) adjuvant therapy for 3 months. All patients received 800 mg daily and Pegasys 180 ucg weekly. Patients in the experimental group received erythropoietin when dose reduction was indicated (HGB < 9). The dose of Ribavirin and Pegasys in the control group was decreased when HGB < 9 and these patients did not receive adjuvant therapy at all. T-test was used to compare end of treatment response and sustained virological response between two groups. P-value less than 0.05 was considered as significant.
Results: Both groups were comparable at the baseline. End of treatment response in the experimental group was 91% (42 of 46 patients) versus 69% (33 of 48 patients) in the control group (p = 0.01). Sustained virological response was 87% (40 of 46 patients) in the intervention group as compared with 65% (31 of 48 patients) in the control group (p < 0.01).
Conclusion: Adjuvant therapy with erythropoietin over no erythropoietin therapy results in more favourable outcomes in patients with hepatitis C.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|